Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with Chemoradiotherapy in IVB Hypopharyngeal Cancer
NCT05860335Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jul 2021
- Primary completion
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in hypopharyngeal cancer, sponsored by Chinese PLA General Hospital. Primary endpoints: Objective Response Rate at 3 years, Progression-Free Survival at 3 years and 1 more. Started Jul 2021; status: recruiting.
02
Drugs
toripalimab
03
Conditions
hypopharyngeal cancer
Beyond the preview
Go deeper on NCT05860335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05860335.